ATS is evolving from lumpy custom automation into a stickier, higher-margin Life Sciences and services platform—while the market still discounts it for legacy EV/project risk.
Overview
ATS is a global manufacturing automation integrator (founded 1978; HQ Cambridge, Ontario) with ~7,500 employees and a broad footprint (65+ manufacturing facilities; 85 offices). It designs, builds, installs, commissions, and services custom and standardized automation systems for complex, regulated, and technology-intensive industries. Revenue is organized into (1) construction contracts (bespoke integrated lines), (2) sale of goods (standard platforms/equipment and lab products), and (3) services (aftermarket support, spares, preventive maintenance, and digital software integration). The company has repositioned away from cyclical automotive toward defensive, higher-margin verticals—especially **Life Sciences**, which represents ~55% of the **$2.05B–$2.14B** backlog. A key strategic objective is expanding recurring services (now ~26.8% of revenue; +29.4% YoY in Q3 FY2026) to reduce project lumpiness and lift margins.